Cytori Therapeutics (CYTX) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Maxim Group Downgrades Cytori Therapeutics, Inc. (CYTX) to Hold
August 15, 2018 7:40 AM EDTMaxim Group analyst Jason McCarthy downgraded Cytori Therapeutics, Inc. (NASDAQ: CYTX) from Buy to Hold and removes their price target.
McCarthy said their fundamental view around the company's key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but... More
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $5 at H.C. Wainwright on Rising Share Count
August 15, 2018 7:12 AM EDTH.C. Wainwright analyst Jason Kolbert lowered the price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $6.00) while maintaining a Buy rating.
Kolbert notes while catalysts lay ahead they are lowering the price target on a rising share... More
